This 'Schizophrenia - Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted schizophrenia epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Schizophrenia Detailed Epidemiology Segmentation
Total prevalent population of schizophrenia in the 7MM was 5,969,144 in 2020. These cases of schizophrenia in the 7MM is expected to increase throughout the study period, i.e., 2018-2030.
Total diagnosed prevalent population of schizophrenia in the 7MM was observed to be 3,043,148 in 2020.
Among the European five countries, Germany has the highest diagnosed prevalent population followed by the United Kingdom and France. On the other hand, Spain had the lowest diagnosed prevalent population.
In the epidemiology model of schizophrenia, there are multiple age groups referred ranging from 18-24 Years; 25-34 Years; 35-44 Years; 45-54 Years; 55-64 Years and 65+ Years for schizophrenia in the US. The highest was 371,697 in the age group 35-44 Years, in 2020, in the US.
Men with schizophrenia appear to have more negative symptoms and more severe clinical features than females, particularly in social withdrawal, substance abuse, and blunted or incongruent affects than female patients.
In 2020, the diagnosed prevalent population of mild schizophrenia was 317,745, which accounted for 22.00% of the total diagnosed cases of schizophrenia, in the United States.
According to the publisher, the majority of cases of Schizophrenia are male as compared to female, in the US and EU-5. But in Japan the diagnosed cases of females represents majority of the cases.
Scope of the Report
The report covers the descriptive overview of schizophrenia, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of schizophrenia.
The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of schizophrenia, Total Diagnosed and Treated Cases of schizophrenia.
10-Year Forecast of schizophrenia
Prevalent Cases of schizophrenia in 7MM
Diagnosed Prevalent cases of schizophrenia in 7MM
Gender-specific Diagnosed Prevalent cases of schizophrenia in 7MM
Age-specific Diagnosed Prevalent cases of schizophrenia in 7MM
Severity-specific Diagnosed Prevalent cases of schizophrenia in 7MM
Key Questions Answered
What is the disease risk, burden and unmet needs of schizophrenia?
What is the historical schizophrenia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
What would be the forecasted patient pool of schizophrenia at the 7MM level?
What will be the growth opportunities across the 7MM with respect to the patient population pertaining to schizophrenia?
Out of the countries mentioned above, which country would have the highest prevalent population of schizophrenia during the forecast period (2021-2030)?
At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?
Reasons to Buy
Develop business strategies by understanding the trends shaping and driving the 7MM schizophrenia market.
The schizophrenia epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
The schizophrenia epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Key Topics Covered:
1 Key Insights
2 Report Introduction
3 Executive Summary of Schizophrenia
4 Disease Background and Overview
4.2 Early warning signs and symptoms of schizophrenia
4.3 Risk factors of schizophrenia
4.4 Subtypes of schizophrenia
4.5 Mechanism of schizophrenia
4.6 Genetics of schizophrenia
4.8 Differential Diagnosis
4.9 Treatment and Management
4.9.1 Acute-phase symptoms
18.104.22.168 Pre-treatment assessment
4.9.2 Medication (Antipsychotic)
4.9.4 Psychosocial Therapy
4.9.5 Electroconvulsive Therapy (ECT)
4.9.6 IPAP schizophrenia Algorithm
4.9.7 Treatment guidelines
22.214.171.124 The American Psychiatric Association (APA) practice guideline for the treatment of patients with schizophrenia
126.96.36.199 The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations
188.8.131.52 Updated schizophrenia port treatment recommendations: psychosocial treatment recommendations
5 Epidemiology and Patient Population
5.1 Key Findings
5.2 Epidemiology Methodology
5.3 Total Prevalent Cases of Schizophrenia in the 7MM
5.4 Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM
5.5 United States Epidemiology
5.5.1 Assumptions and Rationale
5.5.2 Prevalent Cases of schizophrenia in the United States
5.5.3 Diagnosed prevalent cases of schizophrenia in the United States
5.5.4 Gender-specific Diagnosed Prevalent cases of schizophrenia in the United States
5.5.5 Age-specific Diagnosed Prevalent cases of schizophrenia in the United States
5.5.6 Severity-specific Diagnosed Prevalent cases of schizophrenia in the United States
5.6 EU5 Epidemiology
5.6.1 Germany Epidemiology
5.6.2 France Epidemiology
5.6.3 Italy Epidemiology
5.6.4 Spain Epidemiology
5.6.5 United Kingdom Epidemiology
5.7 Japan Epidemiology
6 KOL Views
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/fgvgxc
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005429/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900